Neglected Tropical Disease Treatment Market Revenue Growth Expected to Reach $4.78 Billion by 2030 with 6% CAGR
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Value Is Expected For The Neglected Tropical Disease Treatment Market At The End Of The 2026–2030 Forecast Period?
The neglected tropical disease treatment market has witnessed substantial growth in recent years. It is projected to increase from $3.57 billion in 2025 to $3.8 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.3%. This historic expansion can be ascribed to factors such as the enduring prevalence of these diseases in tropical areas, support from global health organizations, the expansion of donor-funded treatment programs, the availability of generic therapeutics, and heightened public health awareness initiatives.
The neglected tropical disease treatment market size is expected to show significant expansion over the next few years, with projections indicating it will reach $4.79 billion by 2030, advancing at a compound annual growth rate (CAGR) of 6.0%. This anticipated growth during the forecast period is primarily fueled by rising investments in eradication programs, the increasing adoption of integrated disease management strategies, the ongoing development of novel antiparasitic drugs, a rise in public-private partnerships, and a heightened focus on enhancing healthcare access in remote areas. Furthermore, key trends anticipated in this period include the increased deployment of combination drug therapies, a growing emphasis on early disease detection programs, expanded use of mass drug administration strategies, the development of community-based treatment models, and an intensified focus on treatment accessibility.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24616&type=smp
What Primary Drivers Are Shaping The Development Of The Neglected Tropical Disease Treatment Market?
The anticipated growth of the neglected tropical disease treatment market is linked to the increasing occurrence of infectious diseases. These illnesses originate from harmful microorganisms like bacteria, viruses, fungi, or parasites, capable of direct or indirect transmission between individuals. The heightened incidence of infectious diseases stems from greater travel, which expedites the cross-border dissemination of pathogens. Neglected tropical disease treatment supports the management of infectious diseases by offering specific therapies to curb and eradicate disease transmission. Such treatments enhance public health, particularly for susceptible populations, by alleviating disease impact and preventing enduring disabilities. For instance, the UK Health Security Agency reported in February 2024 that tuberculosis cases in England climbed to 4,850 in 2023, representing an increase of 10.7% from 4,380 cases in 2022. Consequently, the growing prevalence of infectious diseases is a key factor driving the expansion of the neglected tropical disease treatment market.
What Segment Types Make Up The Neglected Tropical Disease Treatment Market?
The neglected tropical disease treatment market covered in this report is segmented –
1) By Drug Class: Anti-Parasite, Antifungal, Antibiotics, Other Drugs Class
2) By Disease Type: Leishmaniasis, Schistosomiasis, Lymphatic Filariasis, Chagas Disease, African Trypanosomiasis, Other Disease Types
3) By Route of Administration: Oral, Parenteral
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
5) By End User: Hospital, Specialty Clinics, Homecare Settings, Other End Users
Subsegments:
1) By Anti-Parasite: Anthelmintics, Antiprotozoals, Antimalarials, Ectoparasiticides
2) By Antifungal: Azoles, Polyenes, Allylamines, Echinocandins
3) By Antibiotics: Tetracyclines, Macrolides, Rifamycins, Sulfonamides
4) By Other Drug Classes: Antivirals, Corticosteroids, Combination Therapies, Supportive Treatments
What Key Developments And Trends Are Impacting The Neglected Tropical Disease Treatment Market?
Major companies engaged in the neglected tropical disease treatment market are dedicating efforts to developing innovative solutions, including all-oral, field-deployable therapeutics, with the goal of simplifying administration, improving safety, and expanding access in low-resource environments. All-oral therapeutics for conditions such as human African trypanosomiasis feature small-molecule drugs taken by mouth over a short duration, which helps enhance treatment reach, diminish the necessity for hospitalization, and lower operational barriers when compared with traditional injectable therapies. For example, in December 2023, Sanofi S.A., a France-based multinational pharmaceutical company, introduced Fexinidazole Winthrop, an oral treatment created in collaboration with not-for-profit organizations. Fexinidazole is a nitro-containing small molecule intended to replace older regimens that required intravenous administration or inpatient care. Its oral formulation, streamlined dosing schedule, and favorable safety profile make it suitable for application across both stages of certain forms of sleeping sickness, thereby increasing treatment accessibility in remote areas. Moreover, Fexinidazole stands in contrast to conventional alternatives like melarsoprol and eflornithine, which are injectable, necessitate complex monitoring, and carry higher toxicity or operational challenges.
Who Are The Key Players Driving Competition In The Neglected Tropical Disease Treatment Market?
Major companies operating in the neglected tropical disease treatment market are Pfizer Inc, Johnson And Johnson, Merck And Co Inc, AbbVie Inc, Bayer AG, Novartis AG, Sanofi SA, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc, Eisai Co Ltd, Shionogi And Co Ltd, Dr Reddys Laboratories Ltd, Cipla Ltd, Gilead Sciences Inc, Bristol Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Lupin Limited, Alvogen
Read the full neglected tropical disease treatment market report here:
How Does The Neglected Tropical Disease Treatment Market Perform Across Major Global Regions?
Asia-Pacific was the largest region in the neglected tropical disease treatment market in 2025. The regions covered in the neglected tropical disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Neglected Tropical Disease Treatment Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=24616&type=smp
Browse Through More Reports Similar to the Global Neglected Tropical Disease Treatment Market 2026, By The Business Research Company
Benign Prostatic Hyperplasia Bph Treatment Devices And Equipment Global Market Report
Pain Management Devices And Therapies Global Market Report
Defibrillator Devices And Equipment Global Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
